News Background

Oxford, UK – 21 March 2012. OGT, provider of innovative genetics research and biomarker solutions to advance molecular medicine, has today released the latest addition to its range of CytoSure® ISCA microarrays for reliable and standardised genomic aberration detection. The new patent pending CytoSure ISCA +SNP (4x180k) array combines array comparative genomic hybridisation (aCGH) probes, endorsed by the International Standards for Cytogenomic Arrays (ISCA) Consortium, with fully validated single nucleotide polymorphism (SNP) content. This allows the accurate and cost-effective detection of copy number changes and loss of heterozygosity (LOH) using a single array. As the newest member of the CytoSure ISCA array portfolio, the CytoSure ISCA +SNP array includes enhanced SNP coverage for high-resolution LOH detection.  This means that the analysis of genetically complex samples from related individuals is now even more accurate and in-depth, while integration with OGT’s powerful and intuitive CytoSure Interpret Software ensures that analysis is easy, fast and insightful.

James Clough, Vice President Clinical and Genomic Solutions at OGT, commented: “For several years, OGT has worked closely with ISCA to design a range of arrays focused on providing standardised, evidence-based content. The latest CytoSure ISCA +SNP design is part of our ongoing commitment to further enhancing the accuracy, reproducibility and efficiency of genomic analysis using microarrays, by creating powerful, multi-feature arrays that generate as much relevant data as possible.”

Although aCGH is the gold standard for detecting copy number variation (CNV), until recently it was not possible to combine this technique with LOH and uniparental disomy (UPD) detection using SNP probes. This meant that either two separate arrays were needed, or that inferior SNP-based CNV detection platforms were used. To solve this problem, the CytoSure ISCA +SNP array allows CNV and SNP detection to be carried out on a single array, using optimised probes that are fit for each purpose. By allowing both methods to work efficiently under standard CytoSure aCGH hybridisation conditions, these arrays fit seamlessly into existing workflows. To provide as much relevant information as possible, the arrays include content specifically designed to focus on disease and syndrome-associated regions, in addition to offering whole genome ‘backbone’ coverage.

To simplify the analysis of samples such as those suspected of exhibiting UPD, OGT provides all users of CytoSure arrays with its industry-leading CytoSure Interpret Software. With various innovative features, the software maximises the ease, consistency and speed of data interpretation, while minimising the need for user intervention. The results provided include extensive annotation tracks covering syndromes, genes, exons, CNVs and recombination hotspots, while links to publicly available databases put results into context. Using the comprehensive range of CytoSure products, the transition from sample to biological insight is always fast, accurate and reliable.

About OGT

OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell®, CytoSure® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers - not only by sharing its expertise of 25 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership—together—we’ll achieve more.

 

For more information on the Company, please visit our website at ogt.com

 

CytoSure®, SureSeq™ and myProbes®: For Research Use Only, not for use in diagnostic procedures. CytoCell: Some products may not be available in your region.

 

About Sysmex Corporation

Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 50 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 9,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange.

 

For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/.

  • Share

You might also be interested in

NHS study confirms higher reporting rate for OGT's CytoSure v3 array Listing Image

NHS study confirms higher reporting rate for OGT's CytoSure v3 array

22 Jul 2020

Paper published in npj Genomic Medicine demonstrates identification of more reportable CNVs with CytoSure v3 vs traditional array design.

Read
OGT launches breakthrough NGS panel for constitutional cytogenetics Listing Image

OGT launches breakthrough NGS panel for constitutional cytogenetics

30 Jan 2020

Robust panel enables accurate and comprehensive constitutional genetic aberration screening in one assay.

Read
OGT develops transformative constitutional NGS panel Listing Image

OGT develops transformative constitutional NGS panel

10 Dec 2019

CytoSure™ NGS – Combining the benefits of microarrays and NGS in a single assay.

Read
All News
CTA Icon

Stay up-to-date with the latest news from OGT, including new products, support resources, and our DNA Dispatch newsletter